Contact us
Our history
SSI Diagnostica Group has roots dating back to the early 1900s at the renowned Statens Serum Institut. Today, we have +600 employees and operate offices in Denmark, the United States, and China, ensuring proximity to our customers and patients across all continents. Each year, we deliver diagnostic solutions in more than 130 countries, helping over 60 million people receive the right diagnosis and, ultimately, the right treatment as quickly as possible. SSI Diagnostica is the result of a series of acquisitions, where the following five companies has become one: SSI Diagnostica, CTK Biotech, Beijing Genesee Biotech, TECHLAB, and Gulf Coast Scientific. Read more about or scientific legacy and how we came to be one company below.
Read About us | Read more about the management team | Follow us on LinkedIn
1902
Statens Serum Institut is founded
The origin of SSI Diagnostica Group’s scientific legacy.
1938
Pneumococcus
Statens Serum Institut develops sera for treatment of pneumococcal infections at a time where antibiotics and penicillin was not widely available, providing patients with life-saving treatment
1989
TECHLAB is founded:
Marks the beginning of SSI Diagnostica Group’s portfolio of gastric products in intestinal inflammation, c. diff, h. pylori, parasites, etc.
1992
First FDA approval
TECHLAB’s first FDA-cleared assay, launching decades of C. difficile innovation and 14 more gastric FDA approvals within 9 years.
1998
SSI Diagnostica spun out as an independent business unit
Spun out as a standalone business unit to focus on diagnostic innovation and commercialization.
1999
CTK Biotech founded
Marks the beginning of SSI Diagnostica Group’s bloodborne product portfolio, and high-quality products for use in third world countries.
2000s
QUIK CHEK technology introduced
In early 2000s, TECHLAB develops a new technology; QUIK CHEK, which would come to include more than 10 additionally FDA approved assays over the coming years
2005
Beijing Genesee Biotech facility established
Founding of our manufacturing capabilities in China
2005
First dengue assay
CTK Biotech develops the Dengue IgG/IgM rapid test, becoming the first dengue rapid test in the group, and starts supplying the world with diagnostic solutions in a disease that is rapidly spreading
2007 – 2013
WHO approvals for Malaria test
CTK Biotech starts to get WHO approved malaria test to support public health in tropical and low-resource settings
2009
FDA approval of C. DIFF QUIK CHEK COMPLETE
Solidifies the group’s leadership in C. difficile testing, making the QUIK CHEK COMPLETE a flagship in our QUIK CHEK technology and a global frontrunner in C. difficile testing.
2014
ImmuView P&L developed
A breakthrough in simultaneous pneumococcus and legionella antigen detection, becoming a flagship product in our respiratory portfolio, enabling fast and accurate diagnosis for patients worldwide SSI Diagnostica acquired by Adelis Equity Partners Marked a new era of strategic investments and expansion
2020
CTK Biotech and BGB acquired by Adelis, SSI Diagnostica Group formed
Uniting three companies with complementary strength into a global diagnostic group. CTK and BGB brings an extensive portfolio of lifesaving bloodborne diagnostic solutions into the SSID Group portfolio, including Malaria, HIV, Syphilis, Dengue, Hepatitis and much more
2021
COVID-19 Ag Self-test receives WHO EUL approval
First product co-created by CTK and SSI teams, gaining WHO endorsement ahead of Abbot, Roche and Siemens as the FIRST company.
2022
TECHLAB joins SSI Diagnostica Group
TECHLAB adds an extensive gastric product portfolio to SSI Diagnostica Group, adding decades of renowned expertise in products such as C. difficile, H. pylori, foodborne pathogens, intestinal inflammation and parasites.
2023
Group Strategy formation & innovation as one company
All companies formulate a joint strategy and start commercialization of each other’s portfolios in sales channels. New product development and innovation focus on the full group portfolio to develop the best possible products for customers.
2025
Gulf Coast Scientific joins SSI Diagnostica Group
Adds a complimentary portfolio of Urea breath test to SSI Diagnostica Groups portfolio. Urea breath tests allow SSID Group to offer a broader range of diagnostic solutions to labs with different preferences and clinical needs.
Get in touch
If you have any questions, comments, or collaboration inquiries, you are very welcome to reach out.
Please fill in the form and we will get back to you as soon as possible.